kick schreef op 8 januari 2016 10:23:
[...]
Ik had een mailtje gestuurd naar Synergy. Tot mijn verbazing binnen 8 uur bericht. Niet zo heel veelzeggende e-mail maar wel goed om te lezen dat alles nog steeds op schema ligt.
Thank you for your email and interest in Synergy.
We intend to file our first NDA with plecanatide for CIC this month (January 2016).
We plan to release top-line data from the first phase 3 IBS-C trial in 1H 2016 and top-line data from the second phase 3 IBS-C trial is expected in 2H 2016. We intend to file our second NDA with plecanatide for IBS-C by year-end 2016.
Synergy controls 100% of the worldwide rights to plecanatide. We will continue to evaluate all strategic options to optimize the value of this product and provide the highest return to our shareholders.
I hope this addresses all of your queries. This is poised to be a very exciting year for Synergy and we appreciate your continued support.
Best wishes,
Gem